German biotechnology company MorphoSys AG (MPSYY.PK) presented updated safety and efficacy data from an ongoing clinical phase 1/2a study evaluating the anti-CD38 antibody MOR202 alone and in combination with immunomodulatory drugs lenalidomide and pomalidomide plus dexamethasone in 63 heavily pre-treated patients with relapsed/refractory multiple myeloma or MM.
from RTT - Biotech http://ift.tt/24tihE8
via IFTTT
No comments:
Post a Comment